MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/go-25-00376

Медицинская библиотека · JCO global oncology · 2025

Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Massari Francesco, Rosellini Matteo, Melichar Bohuslav, Grande Enrique, Bourlon Maria T, Li Haoran, Fiala Ondřej, Park Se Hoon, Fita Maria José Juan, Taha Tarek, Molina-Cerrillo Javier, Santini Daniele, de Liañ Alfonso Gómez, Büttner Thomas, Scagliarini Sarah, Manneh Kopp Ray, Zeppellini Annalisa, Ghosn Marwan, Conteduca Vincenza, Bölek Hatice, Rizzo Alessandro, Ansari Jawaher, Mollica Veronica, Zgura Anca, Filosa Alessandra, Yildirim Ahmet, Akova Umut, Monteiro Fernando Sabino Marques, Buti Sebastiano, Soares Andrey, Bilen Mehmet Asim, Ürün Yüksel, Santoni Matteo

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Sarcomatoid renal cell carcinoma (sRCC) represents a kidney malignancy with a sarcomatoid component associated with poor prognosis. Immunotherapy (IO)-based combinations demonstrated promising activity in sRCC, yet real-world evidence (RWE) remains limited. We aimed to characterize the clinicopathologic features and outcomes of patients with metastatic sRCC treated with first-line immune-based combinations.

PATIENTS AND

METHODS

This retrospective analysis from the ARON-1 study included 350 patients with histologically confirmed metastatic sRCC treated with first-line IO + IO, or IO + tyrosine kinase inhibitor across 66 centers in 21 countries (2016-2024). Overall survival (OS) was analyzed using Kaplan-Meier and Cox regression methods. Correlations between 2-year OS and clinical variables were assessed using Pearson's coefficient.

RESULTS

After a median follow-up of 19.1 months, median OS was 26.9 months (95% CI, 21.6 to 43.3). OS was longer in males (43.3 v 15.3 months in females; P < .001), in whom underwent nephrectomy (32.3 v 20.7 months; P = .002), and in patients without hepatic (32.3 v 15.3 months; P < .001), without skeletal (41.0 v 20.0 months; P = .007), or without lymph node metastases (43.3 v 24.6 months; P = .037). Median OS varied by International Metastatic RCC Database Consortium (IMDC) risk group: 66.5, 29.4, and 11.7 months in favorable-, intermediate-, and poor-risk patients, respectively (P < .001). Different IO regimens showed variable outcomes by risk subgroup. Limitations include retrospective design and lack of central pathology review.

CONCLUSION

First-line IO-based combinations provide clinically meaningful survival in sRCC, with outcomes affected by sex, metastatic sites, and IMDC risk. This RWE may support a tailored therapeutic approach on the basis of baseline prognostic factors.

Для цитирования: Massari Francesco, Rosellini Matteo, Melichar Bohuslav, Grande Enrique, Bourlon Maria T, Li Haoran, Fiala Ondřej, Park Se Hoon, Fita Maria José Juan, Taha Tarek, Molina-Cerrillo Javier, Santini Daniele, de Liañ Alfonso Gómez, Büttner Thomas, Scagliarini Sarah, Manneh Kopp Ray, Zeppellini Annalisa, Ghosn Marwan, Conteduca Vincenza, Bölek Hatice, Rizzo Alessandro, Ansari Jawaher, Mollica Veronica, Zgura Anca, Filosa Alessandra, Yildirim Ahmet, Akova Umut, Monteiro Fernando Sabino Marques, Buti Sebastiano, Soares Andrey, Bilen Mehmet Asim, Ürün Yüksel, Santoni Matteo. Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.. JCO global oncology. 2025. DOI: 10.1200/go-25-00376.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.